Martin van Eickels
Bayer (Germany)(DE)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Cardiac Arrhythmias and Treatments, Venous Thromboembolism Diagnosis and Management, Antiplatelet Therapy and Cardiovascular Diseases, Cardiac electrophysiology and arrhythmias
Most-Cited Works
- → Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI(2016)1,535 cited
- → Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation(2009)1,122 cited
- → Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway(2000)467 cited
- → XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation(2015)449 cited
- → Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry(2013)441 cited
- → Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation(2014)365 cited
- → Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A(2003)333 cited
- → 17β-Estradiol Attenuates the Development of Pressure-Overload Hypertrophy(2001)302 cited
- → Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter(2009)263 cited
- → Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study(2015)244 cited